Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : Mdwd save search
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
Published: 2023-04-26 (Crawled : 13:20) - globenewswire.com
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: -1.6%
H: 4.46%
C: -3.26%
escharex symposium care spring phase 2
MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
Published: 2022-05-12 (Crawled : 11:00) - globenewswire.com
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 3.33%
H: 3.23%
C: 2.69%
trial positive phase 2
MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds
Published: 2022-03-21 (Crawled : 13:30) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 2.04%
H: 0.5%
C: -3.5%
phase 2 trial
MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
Published: 2022-01-24 (Crawled : 12:00) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: -1.57%
H: 5.6%
C: 0.4%
phase 2 trial topline results positive topline
MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds
Published: 2021-12-20 (Crawled : 15:00) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: -0.82%
H: 1.24%
C: -2.89%
phase 2 positive
MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design StudyTopline Data Expected in the First Quarter of 2022
Published: 2021-12-06 (Crawled : 15:00) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: 0.0%
phase 2 topline enroll designation
MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
Published: 2021-12-06 (Crawled : 12:30) - globenewswire.com
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: 0.0%
phase 2 enroll designation
MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study
Published: 2021-07-28 (Crawled : 12:00) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: -0.98%
H: 3.45%
C: -0.99%
phase 2 positive designation
MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal
Published: 2021-07-09 (Crawled : 12:15) - globenewswire.com
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 0.0%
H: 8.08%
C: 5.77%
phase 2 results trial trial results
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design StudyInterim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021
Published: 2021-06-09 (Crawled : 23:00) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 1.08%
H: 6.95%
C: 6.95%
phase 2 enroll designation
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study
Published: 2021-06-09 (Crawled : 21:00) - globenewswire.com
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 0.5%
H: 15.67%
C: 13.68%
phase 2 enroll designation
MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharExData Expected Second-Half 2021
Published: 2021-04-22 (Crawled : 18:00) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 1.92%
H: 2.93%
C: -3.56%
phase 2 enroll
MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx
Published: 2021-04-22 (Crawled : 12:00) - globenewswire.com
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: 1.92%
H: 2.93%
C: -3.56%
phase 2 enroll
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.